Compound ID | 86
Imipenem + cilastatin/relebactam
Synonym(s): MK-7655
Class: Drug combination: beta-lactam (carbapenem) + beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Complicated urinary tract infections (cUTI), acute pyelonephritis, Complicated urinary tract infections (cUTI), acute pyelonephritis, complicated intra-abdominal infections (cIAI), hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (approved by FDA in 2020) |
| Combined with other compounds: | Yes |
| Institute where first reported: | Merck & Co |
| Year first mentioned: | 2011 |
| Highest developmental phase: | Approved by FDA in 2019 |
| Development status: | Approved |
| External links: | |
| Guide to Pharmacology: | cilastatin |
| Citation: | https://clinicaltrials.gov/ct2/show/NCT02452047 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us.
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.